Martinčič Anže, Milačič Radmila, Vidmar Janja, Turel Iztok, Keppler Bernhard K, Sčančar Janez
Department of Environmental Sciences, Jožef Stefan Institute, Jamova 39, 1000 Ljubljana, Slovenia; Jožef Stefan International Postgraduate School, Jamova 39, 1000 Ljubljana, Slovenia.
Faculty of Chemistry and Chemical Technology, University of Ljubljana, Aškerčeva 5, 1000 Ljubljana, Slovenia.
J Chromatogr A. 2014 Dec 5;1371:168-76. doi: 10.1016/j.chroma.2014.10.054. Epub 2014 Oct 24.
An important step in pharmacological characterisation of a candidate drug is the study of the drugs interactions with serum proteins. In the present work, conjoint liquid chromatography (CLC) was used for separation of ruthenium (Ru)-based drug candidates in human serum. CIM Protein G and CIM DEAE disks were assembled together in a single housing forming a CLC monolithic column. By applying isocratic elution with Tris-HCl-NaHCO3 buffer (pH 7.4) in the first min, followed by gradient elution with 1 mol L(-1) NH4Cl (pH 7.4) in the next 9 min, immunoglobulins (IgG) were retained by the Protein G disk enabling subsequent separation of unbound Ru species from Ru species bound to human serum transferrin (Tf) and albumin (HSA) on the CIM DEAE disk. Finally, elution with acetic acid (AcOH) in the next 3 min allowed separation of Ru species associated with IgG. Protein elution was followed on-line with UV detection at 278nm, while the separated Ru species were quantified by post-column isotope dilution inductively coupled plasma mass spectrometry (ID-ICP-MS). The instrumental set-up enabled fast two-dimensional separation by affinity and ion-exchange modes to be carried out in a single chromatographic run. Two Ru-based chemotherapeutics: a newly synthesised compound chlorido(η6-p-cymene)(nalidixicato-κ2O,O)Ru(II) (1) and (H2im)[trans-Ru(III)Cl4(Him)2] (2; KP418), which is currently undergoing preclinical studies, were investigated. The CLC procedure applied is sensitive with low limit of detection (LOD) (0.027 μg Ru mL(-1) for (1)) and good method repeatability (RSD±3.5%). The experimental data revealed that it enables investigation of the kinetics of interaction of positively charged and neutral complexes of metallodrugs with serum proteins as well as the distribution of metallodrug species in human serum. However, negatively charged metallic complexes co-eluted with Tf and HSA and thus hindered their speciation analysis. An example of successful application of the kinetic studies on the CLC column is (1), a neutral Ru complex that hydrolyses to a positively charged species. For comparison, speciation data obtained for serum samples spiked with cisplatin are also shown.
候选药物药理特性表征的一个重要步骤是研究药物与血清蛋白的相互作用。在本研究中,联用液相色谱法(CLC)用于分离人血清中基于钌(Ru)的候选药物。CIM Protein G和CIM DEAE圆盘在单个柱管中组装在一起,形成一个CLC整体柱。首先在第1分钟用Tris-HCl-NaHCO3缓冲液(pH 7.4)进行等度洗脱,随后在接下来的9分钟用1 mol L⁻¹NH4Cl(pH 7.4)进行梯度洗脱,免疫球蛋白(IgG)被Protein G圆盘保留,从而能够在CIM DEAE圆盘上随后分离未结合的Ru物种与结合到人血清转铁蛋白(Tf)和白蛋白(HSA)上的Ru物种。最后,在接下来的3分钟用乙酸(AcOH)洗脱,实现与IgG相关的Ru物种的分离。蛋白质洗脱通过在278nm处的紫外检测进行在线监测,而分离的Ru物种通过柱后同位素稀释电感耦合等离子体质谱法(ID-ICP-MS)进行定量。该仪器设置能够在一次色谱运行中通过亲和和离子交换模式进行快速二维分离。研究了两种基于Ru的化疗药物:一种新合成的化合物氯(η6-对异丙基苯)(萘啶酸根-κ2O,O)Ru(II)(1)和(H2im)[反式-Ru(III)Cl4(Him)2](2;KP418),后者目前正在进行临床前研究。所应用的CLC方法灵敏,检测限低(对于(1)为0.027μg Ru mL⁻¹)且方法重复性良好(RSD±3.5%)。实验数据表明,它能够研究金属药物带正电荷和中性络合物与血清蛋白相互作用的动力学以及金属药物物种在人血清中的分布。然而,带负电荷的金属络合物与Tf和HSA共洗脱,从而阻碍了它们的形态分析。在CLC柱上进行动力学研究成功应用的一个例子是(1),一种中性Ru络合物,它水解为带正电荷的物种。作为比较,还展示了添加顺铂的血清样品获得的形态数据。